Clinical Significance of Dynamics of Programmed Death Ligand-1 Expression on Circulating CD14+ Monocytes and CD19+ B Cells with the Progression of Hepatitis B Virus Infection

Viral Immunology

Volumn 30, Issue 3, 2017, Pages 224-231

  Huang, Zi Yi ^a,b   Xu, Ping ^c   Li, Jian Hua ^d   Zeng, Chen Hua ^a   Song, Hua Feng ^c   Chen, Hui ^c   Zhu, Yi Bei ^a   Song, Ying Ying ^a   Lu, Han Lin ^a   Shen, Chun Ping ^a   Zhang, Xue Guang ^a,b   Wu, Mei Ying ^c   Wang, Xue Feng ^a  

^a SOOCHOW UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c The Affiliated Infectious Diseases Hospital of Soochow University   (China)

^d Central Blood Station of Jiaxing   (China)

Author keywords

B cells; hepatitis B virus infection; monocytes; programmed death ligand 1

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CD14 ANTIGEN; CD19 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; CD19 MOLECULE, HUMAN; CD274 PROTEIN, HUMAN; LIPOPOLYSACCHARIDE RECEPTOR; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; B LYMPHOCYTE; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MOLECULAR DYNAMICS; MONOCYTE; PROTEIN EXPRESSION; VIROLOGY; VIRUS LOAD; BLOOD; CHEMISTRY; CHRONIC HEPATITIS B; COMPLICATION; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; ALANINE TRANSAMINASE; ANTIGENS, CD19; ASPARTATE AMINOTRANSFERASES; B-LYMPHOCYTES; B7-H1 ANTIGEN; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIPOPOLYSACCHARIDE RECEPTORS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MONOCYTES; PROGNOSIS; VIRAL LOAD;

EID: 85017354825     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2016.0122     Document Type: Article

References (33)

1. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439:682-687.
2. Baumert TF, Thimme R, and von Weizsacker F. Pathogenesis of hepatitis B virus infection. World J Gastroenterol 2007;13:82-90.
3. Blackburn SD, and Wherry EJ. IL-10, T cell exhaustion and viral persistence. Trends Microbiol 2007;15:143-146.
4. Boltjes A, Movita D, Boonstra A, and Woltman AM. The role of Kupffer cells in hepatitis B and hepatitis C virus infections. J Hepatol 2014;61:660-671.
5. Boni C, Fisicaro P, Valdatta C, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007;81:4215-4225.
6. Brooks DG, Trifilo MJ, Edelmann KH, et al. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 2006;12:1301-1309.
7. Chen J, Wang XM, Wu XJ, et al. Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B. Inflamm Res 2011;60:47-53.
8. Das A, Ellis G, Pallant C, et al. IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J Immunol 2012;189:3925-3935.
9. Dong H, Zhu G, Tamada K, et al. B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. Immunity 2004;20:327-336.
10. Ejrnaes M, Filippi CM, Martinic MM, et al. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med 2006;203:2461-2472.
11. Fathy A, Eldin MM, Etwally LM, et al. Diminished absolute counts of CD56dim and CD56bright natural killer cells in peripheral blood from Egyptian patients with hepatocellular carcinoma. Egypt J Immunol 2009;16:17-25.
12. Feng C, Cao LJ, Song HF, et al. Expression of PD-L1 on CD4+CD25+Foxp3+ regulatory T cells of patients with chronic HBV infection and its correlation with clinical parameters. Viral Immunol 2015;28:418-424.
13. Fisicaro P, Valdatta C, Massari M, et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 2010;138:682-693, 693 e681-e684.
14. Geng S, Zhong Y, Wang S, et al. Amiloride enhances antigen specific CTL by faciliting HBV DNA vaccine entry into cells. PLoS One 2012;7:e33015.
15. Guidotti LG, and Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006;1:23-61.
16. Guidotti LG, Isogawa M, and Chisari FV. Host-virus interactions in hepatitis B virus infection. Curr Opin Immunol 2015;36:61-66.
17. Han Y, Li J, Jiang L, et al. Regulation of B7-H1 expression on peripheral monocytes and IFN-gamma secretion in T lymphocytes by HBeAg. Cell Immunol 2013;283:25-30.
18. Hsu PN, Yang TC, Kao JT, et al. Increased PD-1 and decreased CD28 expression in chronic hepatitis B patients with advanced hepatocellular carcinoma. Liver Int 2010; 30:1379-1386.
19. Liu J, Hamrouni A, Wolowiec D, et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEKdependent pathway. Blood 2007;110:296-304.
20. Maini MK, Boni C, Lee CK, et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000; 191:1269-1280.
21. Mitchell AE, Colvin HM, and Palmer R. Beasley Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology 2010;51:729-733.
22. Mueller SN, and Ahmed R. High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A 2009;106:8623-8628.
23. Rehermann B, and Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005;5:215-229.
24. Said EA, Alreesi I, Alriyami M, et al. Increased CD86 but not CD80 and PD-L1 expression on liver CD68+ cells during chronic HBV infection. PLoS One 2016;11:e0158265.
25. Schurich A, Khanna P, Lopes AR, et al. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 2011;53:1494-1503.
26. Shi F, Shi M, Zeng Z, et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 2011;128:887-896.
27. Soria JC, Marabelle A, Brahmer JR, and Gettinger S. Immune checkpoint modulation for non-small cell lung cancer. Clin Cancer Res 2015;21:2256-2262.
28. Tzeng HT, Tsai HF, Liao HJ, et al. PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model. PLoS One 2012;7:e39179.
29. Umemoto Y, Okano S, Matsumoto Y, et al. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy. J Gastroenterol 2015; 50:65-75.
30. Xie Z, Chen Y, Zhao S, et al. Intrahepatic PD-1/PD-L1 upregulation closely correlates with inflammation and virus replication in patients with chronic HBV infection. Immunol Invest 2009;38:624-638.
31. Xu P, Chen YJ, Chen H, et al. The expression of programmed death-1 in circulating CD4+ and CD8+ T cells during hepatitis B virus infection progression and its correlation with clinical baseline characteristics. Gut Liver 2014;8:186-195.
32. Zang X, and Allison JP. The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res 2007; 13:5271-5279.
33. Zheng J, Liang H, Xu C, et al. An unbalanced PD-L1/CD86 ratio in CD14(++)CD16(+) monocytes is correlated with HCV viremia during chronic HCV infection. Cell Mol Immunol 2014;11:294-304.